Cryptococcal Meningitis in a Fingolimod-Treated Patient Positive Antigen Test a Year Before Onset

被引：3

作者：

Aoki, Reiji ^{[1
]}

Mori, Masahiro ^{[1
]}

Suzuki, Yo-ichi ^{[1
]}

Uzawa, Akiyuki ^{[1
]}

Masuda, Hiroki ^{[1
]}

Uchida, Tomohiko ^{[1
]}

Ohtani, Ryohei ^{[1
]}

Kuwabara, Satoshi ^{[1
]}

机构：

[1] Chiba Univ, Grad Sch Med, Dept Neurol, Chiba, Japan

来源：

NEUROLOGY-CLINICAL PRACTICE | 2021年 / 11卷 / 04期

关键词：

MULTIPLE-SCLEROSIS;

D O I：

10.1212/CPJ.0000000000001051

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Fingolimod, a sphingosine 1-phosphate receptor modulator, has proven high efficacy for relapsing-remitting multiple sclerosis (MS)1 and is currently widely used for MS treatment. Fingolimod is classified as a second-line treatment2 because of adverse side effects, including bradyarrhythmia, macular edema, and liver dysfunction, as well as fatal infections due to herpes virus, John Cunningham virus (progressive multifocal leukoencephalopathy), and cryptococcus, but it is available as a first-line treatment in Japan. Herein, we report a patient with MS who received fingolimod treatment for 6 years and subsequently developed cryptococcal meningitis (CM). Retrospective testing of stored sera revealed positive conversion of cryptococcal antigen 1 year before the onset of clinical meningitis.

引用

页码：E549 / E550

页数：2

共 7 条

[1] Cryptococcal Meningoencephalitis in a Patient With Multiple Sclerosis Treated With Fingolimod
Achtnichts, Lutz
Obreja, Otilia
Conen, Anna
Fux, Christoph A.
Nedeltchev, Krassen
[J]. JAMA NEUROLOGY, 2015, 72 (10) : 1203 - +
[2] Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings
Chong, Insun
Wang, Kevin Yuqi
Lincoln, Christie M.
[J]. CLINICAL IMAGING, 2019, 54 : 53 - 56
[3] Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature
Grebenciucova, Elena
Reder, Anthony T.
Bernard, Jacqueline T.
[J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2016, 9 : 158 - 162
[4] DISSEMINATED CRYPTOCOCCOSIS IN A PATIENT WITH MULTIPLE SCLEROSIS TREATED WITH FINGOLIMOD
Huang, DeRen
[J]. NEUROLOGY, 2015, 85 (11) : 1001 - 1003
[5] Fingolimod for relapsing-remitting multiple sclerosis
La Mantia, Loredana
Tramacere, Irene
Firwana, Belal
Pacchetti, Ilaria
Palumbo, Roberto
Filippini, Graziella
[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (04):
[6] Disease-modifying treatments for multiple sclerosis - a review of approved medications
Torkildsen, O.
Myhr, K. -M.
Bo, L.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 18 - 27
[7] Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy
Williamson, Peter R.
Jarvis, Joseph N.
Panackal, Anil A.
Fisher, Matthew C.
Molloy, Sile F.
Loyse, Angela
Harrison, Thomas S.
[J]. NATURE REVIEWS NEUROLOGY, 2017, 13 (01) : 13 - 24

← 1 →